SCHEMBL344736

SCHEMBL344736

CCOC(=O)c1ccc(-c2ccc(OCCCCO[Si](C)(C)C(C)(C)C)c(-c3ccc4c(c3)C(C)(C)CCC4(C)C)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RARG P13631 18/20 0.60
RARB P10826 9/20 0.60
RARA P10276 9/20 0.60
RXRA P19793 1/20 0.45
PDK2 Q15119 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345649 0.98 RARG (0.58) RARGRARBRARARXRAPDK2
SCHEMBL3876602 0.90 RARG (0.75) RARGRARBRARARXRA
SCHEMBL3877740 0.88 RARG (0.73) RARGRARBRARARXRA
SCHEMBL956982 0.87 RARG (0.67) RARGRARBRARARXRA
SCHEMBL345356 0.87 RARG (0.79) RARGRARBRARARXRA
SCHEMBL957264 0.86 RARG (0.66) RARGRARBRARARXRA
SCHEMBL5846621 0.86 RARG (0.77) RARGRARBRARARXRA
SCHEMBL959254 0.86 RARG (0.66) RARGRARBRARARXRA
SCHEMBL343651 0.86 RARG (0.78) RARGRARBRARARXRA
SCHEMBL10002006 0.86 RARG (0.71) RARGRARBRARARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362082-B2 Biphenyl compound selective agonists of gamma RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-01-29 US disclosed
US-20120016031-A1 BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-01-19 US disclosed
US-8049034-B2 Biphenyl compound selective agonists of gamma RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-01 US disclosed
US-20090023811-A1 Biphenyl compound selective agonists of gamma RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023811-A1 Biphenyl compound selective agonists of gamma RAR receptors RARG, RARB, RARA RARG 1/4885RARB 2/4885RARA 3/4885
US-20120016031-A1 BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS RARG, RARB, RARA RARG 1/4885RARB 2/4885RARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.